Responses
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
SAT0177 The Combination of Serum Matrix Metalloproteinase-3 and C-Reactive Protein at 4 Weeks Predict High Continuation Rate in RA Patients with Adalimumab Therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.